ASCO 2022 and Immuno Oncology View overview page

1:13
Promising future of PSMA for prostate cancer
Eugene Shenderov • 10 Jun 2022
6:57
Phase II trial of enoblituzumab for patients with intermediate/high-risk localised prostate cancer
Eugene Shenderov • 10 Jun 2022
1:17
MK-0482-001: evaluating MK-0482 plus pembrolizumab in patients with advanced solid tumors
Andre Goy • 5 Jun 2022
4:53
Phase I trial of mRNA neoantigen vaccines for pancreatic cancer
Vinod P. Balachandran • 16 Jun 2022
3:17
Development of individualized mRNA neoantigen vaccines for pancreatic cancer
Vinod Balachandran • 16 Jun 2022
1:31
Potential of immunotherapy for pancreatic cancer
Vinod P. Balachandran • 16 Jun 2022
2:01
Salvage CT041 CLDN18.2-specific CAR T-cell therapy for patients with advanced GI malignancies
Gregory P. Botta • 13 Jun 2022
0:34
Expanding indications for a CLDN18.2-specific CAR T-cell therapy in GI cancers
Gregory P. Botta • 13 Jun 2022
2:16
Safety and efficacy of a CLDN18.2-specific CAR T-cell therapy in GI adenocarcinoma
Gregory P. Botta • 13 Jun 2022
4:29
Pertuzumab, trastuzumab and cyclophosphamide in older patients with HER2+ breast cancer
Thomas Meyskens • 30 May 2022
0:55
Future directions for CLDN18.2-specific CAR T-cell therapy in GI cancers
Gregory P. Botta • 13 Jun 2022
1:25
Phase II study of neoadjuvant atezolizumab with gemcitabine and cisplatin in patients with MIBC
Jonathan Rosenberg • 5 Jun 2022
2:04
Areas of unmet need in metastatic urothelial carcinoma
Robert Jones • 4 Jun 2022
1:16
Colorectal cancer updates at ASCO 2022
Mark Yarchoan • 5 Jun 2022
2:26
Overcoming barriers in treating melanoma brain metastases
Bently Doonan • 7 Jun 2022
3:51
Evaluating the mechanism of action of emavusertib
Bently Doonan • 7 Jun 2022
The content of VJOncology is intended for healthcare professionals